Delivering Unprecedented Access to Biosimilars in Global Markets
CONTACT  |  SITE MAP
  • Building a focused, sustainable and profitable
    biosimilar business
  • Improving patient access to important, cost-effective
    medicines worldwide
  • Advancing our products through strategic partnerships
    to maximize future value
Who We Are

EPIRUS is a global biopharmaceutical company focused on building a pure-play, sustainable and profitable biosimilar business by improving patient access through cost-effective medicines.  Our ability to deliver on this vision is anchored in our strong technical platform and pragmatic approach to development and commercialization. We are currently progressing a pipeline of six monoclonal antibodies for autoimmune / inflammatory and rare diseases.

Learn More

News

February 9, 2016

EPIRUS Biopharmaceuticals Initiates Pivotal Global Phase 3 Clinical Study for BOW015 (Infliximab Biosimilar)

February 5, 2016

EPIRUS Biopharmaceuticals to Participate in Bloomberg Intelligence Healthcare Event on February 12

 

Events

February 12, 2016

EPIRUS Biopharmaceuticals to Participate in Bloomberg Intelligence Healthcare Event on February 12

February 10, 2016

EPIRUS Biopharmaceuticals to Present at LEERINK Partners 5th Annual Global Healthcare Conference

 

Bookmark and Share